- •Disparities in Stage IV cancer outcomes were identified using NCBD data.
- •Outcomes in pancreatic, colorectal, lung, breast, and prostate cancer were compared.
- •Differences in surgery, chemotherapy and radiation therapy treatments were found.
- •Black, low-income, uninsured, and Medicare/Medicaid patients had worse survival.
- •Adjusting for differences in treatments did not eliminate the worse survival.
Disparities in cancer outcomes for minoritized people and groups experiencing disadvantages with Stage IV cancer is largely unknown.
Patients with Stage IV pancreatic, colorectal, lung, breast, and prostate cancer were identified from 2004 to 2015 in the National Cancer Database. Cox proportional hazard models were used to quantify how demographics and treatments received were associated with overall survival.
903,151 patients were included. Patients who were younger, non-Hispanic White, had private insurance, higher income, or received care at an academic center were more likely to receive surgery, chemotherapy, and/or radiation therapy (p < 0.001). Black patients, those with Medicare, Medicaid, no insurance, and lower income had lower survival rates across all five cancer types (p < 0.001). On multivariable analysis, receipt of surgery, radiation, and chemotherapy attenuated but did not eliminate this worse survival (p < 0.001).
Survival for patients with Stage IV cancer differs by socioeconomic and self-reported racial classifications.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.Cancer Epidemiol Prevent Biomarkers. 2015; 24: 1666-1672
- Disparities in breast cancer survival by socioeconomic status despite Medicare and Medicaid insurance.Milbank Q. 2018 Dec; 96 (PubMed PMID: 30537364. Pubmed Central PMCID: PMC6287075. Epub 2018/12/12. eng): 706-754
- Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014.Cancer. 2019 Jul 8; 25 (PubMed PMID: 31282032. Epub 2019/07/10. eng. 1): 3412-3417
- Black/white differences in treatment and survival among women with stage IIIB-IV breast cancer at diagnosis: a US population-based study.Cancer Causes Control. 2018 Jul; 29 (PubMed PMID: 29860614. Epub 2018/06/04. eng): 657-665
- Affluence does not influence breast cancer outcomes in african American women.J Health Care Poor Underserved. 2018; 29 (PubMed PMID: 29503315. Epub 2018/03/06. eng): 509-529
- Effects of cancer stage and treatment differences on racial disparities in survival from colon cancer: a United States population-based study.Gastroenterology. 2016 May; 150 (PubMed PMID: 26836586. Pubmed Central PMCID: PMC4842115. Epub 2016/02/03. eng): 1135-1146
- Health disparities impact expected treatment of pancreatic ductal adenocarcinoma nationally.Ann Surg Oncol. 2018 Jul; 25 (PubMed PMID: 29691733. Epub 2018/04/25. eng): 1860-1867
- Disparities in resection of hepatic metastases in colon cancer.J Gastrointest Oncol. 2018 Feb; 9 (PubMed PMID: 29564178. Pubmed Central PMCID: PMC5848028. Epub 2018/03/23. eng): 126-134
- Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance.Cancer Epidemiol Biomarkers Prev. 2019 Jun; 28 (PubMed PMID: 30842132. Epub 2019/03/08. eng): 1059-1066
- Disparities and trends in genetic testing and erlotinib treatment among metastatic non-small cell lung cancer patients.Cancer Epidemiol Biomarkers Prev. 2019 May; 28 (PubMed PMID: 30787053. Pubmed Central PMCID: PMC6500471. Epub 2019/02/23. eng): 926-934
- Race, poverty, and initial implementation of precision medicine for lung cancer.J Natl Cancer Inst. 2019 Apr 1; 111 (PubMed PMID: 30576459. Pubmed Central PMCID: PMC6449167. Epub 2018/12/24. eng): 431-434
- Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: a SEER-Medicare investigation.Cancer Med. 2019; 8: 3325-3335
- Differences in stage of cancer at diagnosis, treatment, and survival by race and ethnicity among leading cancer types.JAMA Netw Open. 2020 Apr 1; 3 (PubMed PMID: 32267515. Pubmed Central PMCID: PMC7142383. Epub 2020/04/09. eng)e202950
- Cancer facts and statistics.American Cancer Society. 2023; (Available from:)
- Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients: a single‐institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and end results database.Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007; 110: 876-884
- Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using seer database.Clin Cancer Res. 2019; 25: 1970-1979
- Treatment and survival outcome for molecular breast cancer subtypes in black women.Ann Surg. 2008; 247: 463-469
- Triple-negative breast cancers: a view from 10,000 feet.Cancer J. 2010 Jan-Feb; 16 (PubMed PMID: 20164686. Epub 2010/02/19. eng): 17-22
- Breast cancer survival in African-American women by hormone receptor subtypes.Breast Cancer Res Treat. 2015; 153: 211-218
- Race, breast cancer subtypes, and survival in the carolina breast cancer study.JAMA. 2006; 295: 2492-2502
- Racial disparity in distant recurrence-free survival in patients with localized breast cancer: a pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.Cancer. 2022 Jul 15; 128 (PubMed PMID: 35578919. Epub 2022/05/18. eng): 2728-2735
- Prostate cancer–specific mortality across Gleason scores in black vs nonblack men.JAMA. 2018; 320: 2479-2481
- Research silos in cancer disparities: obstacles to improving clinical outcomes for under-served patient populations.Clin Cancer Res. 2023 Jan 13; 22-3182 (PubMed PMID: 36638200. Epub 2023/01/14)
- Association of residential racial and economic segregation with cancer mortality in the US.JAMA Oncol. 2023 Jan 1; 9 (PubMed PMID: 36394851. Pubmed Central PMCID: PMC9673024 Health Equity Advisory Board, and that all honoraria are donated to the American Cancer Society. Dr Han reported receiving grants from AstraZeneca outside the submitted work. No other disclosures were reported. Epub 2022/11/18. eng): 122-126
- The impact of social and environmental factors on cancer biology in Black Americans.Cancer Causes Control. 2022 Dec 23; 34 (PubMed PMID: 36562901. Epub 2022/12/24): 191-203
- Early palliative care for patients with metastatic non–small-cell lung cancer.N Engl J Med. 2010; 363 (PubMed PMID: 20818875): 733-742
- Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle.J Gastrointest Oncol. 2018; 9: 1014
- Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy.Am Soc Clin Oncol Educat Book. 2019; 39 (PubMed PMID: 31099618): 3-10
- NIMHD research framework.([cited 2023]; Available from:)
- Social determinants of health.(Available from:)
- National cancer database: the Past, present, and future of the cancer registry and its efforts to improve the quality of cancer care.Semin Radiat Oncol. 2019 Oct; 29 (PubMed PMID: 31472733. Epub 2019/09/02. eng): 323-325
- Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration.JAMA Oncol. 2019; 5: 1702-1709
- Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population‐based propensity‐score adjusted study in The Netherlands.Int J Cancer. 2016; 139: 2082-2094
- Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer.N Engl J Med. 2016; 375 (PubMed PMID: 27718847): 1823-1833
- Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP-and immune-checkpoint-inhibitors.Expet Opin Pharmacother. 2020; 21: 687-699
Published online: March 10, 2023
Accepted: March 3, 2023
Received in revised form: February 20, 2023
Received: December 21, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Elsevier Inc. All rights reserved.